Proven Data.
Backed by Research.
18.3 KG
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.
22.5%
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as scientific context.
6oo
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling.
Provided strictly as scientific context
TOP SELLING PRODUCTS
More than peptides.
A Complete Research Platform.
From research-grade compounds to structured data collection and nutritional analysis – Alluvi provides an integrated system designed for controlled research and development programs.
Not for human or veterinary consumption.
Science-Backed Protocols
Our compounds and supplements are supplied for R&D purposes only, with a foundation in published scientific literature, not consumer trends.
Supplement Support
Daily gummies for wellness research applications – curated for structured evaluation of nutrition-focused compounds in controlled study settings.
Consistency is key
Stay on track with monthly research supply boxes.
Retatrutide 20mg uk
Retatrutide 20mg uk The query regarding Retatrutide 20mg UK focuses on a drug that represents [...]
Nov
Retatrutide vs Semaglutide
Retatrutide vs Semaglutide The comparison between Retatrutide and Semaglutide highlights the rapid and escalating advancements [...]
Nov
Retatrutide how to get
Retatrutide how to get Retatrutide is an emerging investigational medication generating significant interest due to [...]
Sep